Ustekinumab achieved the highest clinical and endoscopic response rates in chronic pouchitis, while tofacitinib was linked to more adverse events.

Twelve fecal metabolites are significantly altered among patients with irritable bowel syndrome compared with healthy control individuals.

Increased colorectal cancer screening rates are significantly associated with declining mortality, though racial and socioeconomic disparities persist.

The FDA will complete the approval process for certain medications in 1 to 2 months, a change from the usual 10-month review.

Vitamin D deficiency is significantly more common in pediatric vs adult populations with inflammatory bowel diseases.

Patients with obesity hospitalized with acute pancreatitis who receive GLP-1 RAs have a significantly lower mortality and complication rate at 6 months.

Achieving sustained virological response after direct-acting antiviral therapy reduces liver-related events among those with decompensated HCV cirrhosis.

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

Obeticholic acid added to ursodeoxycholic acid improved alkaline phosphatase and bilirubin levels among patients with PBC unresponsive to first-line therapy.

Cancer survivors who reported currently smoking or having previously smoked had 1.35 and 1.13 times increased rates of all-cause mortality, respectively, compared with patients who never smoked.

A diagnosis of distant breast, colorectal, or non-small cell cancer was less likely among individuals receiving housing assistance than among matched control individuals, compared to a localized ...